Loading…
← CockpitCompetitor Analysis › ABUS Arbutus Biopharma CorporationOpen in the cockpit ↗

Arbutus Biopharma CorporationABUSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 39
Mkt cap
$630M
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$10.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.2%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$4.11
1D+1.5%
1W+5.9%
1M-5.1%
3M-13.8%
6M-6.0%
YTD-14.6%
1Y-9.5%
ATR %4.6%
Beta1.14
52w lowhigh24.6% off high

What Arbutus Biopharma does

Employees: 19

Arbutus Biopharma at a glance

Size Arbutus Biopharma (ABUS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $630M, the 2524th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.11 on 18 Nov 2026.

Performance Over six months the shares fell 6.0%, against -25.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 1,142.6% over the last twelve months (peer median +5.5%); the operating margin is 80.1% (peer median 4.4%).

Valuation It trades at 1.6× enterprise value to sales against a peer median of 3.3× (3rd cheapest of 17).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026ABUS 93Peer median 76
Six months, rebased to 100: Arbutus Biopharma against the median of its 20 peers (local-currency closes).

Arbutus Biopharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$181M$14.1M$6.17M$18.1M$39.0M
Revenue growth—+128%-66%-54%—
Gross profit$181M$13.7M$4.79M$16.7M$37.6M
EBITDA$145M-$26.7M-$68.6M-$76.6M-$61.8M
Net income$220M-$33.5M-$69.9M-$72.8M-$69.5M
Free cash flown/a-$39.6M-$65.0M-$86.9M-$35.9M
Capital expenditure$0$0$182,000$1.01M$512,000
Total debt$3.31M$4.19M$6.12M$8.72M$12.6M

Quarterly statements and history in the cockpit →

Arbutus Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%300878BCAX4123300016301211OLMA000566INNOVACAP4105ORCHPHARMA002940603567FDCDBV300233ABUS6-month return →1-month return →
Up and to the right = strong over both horizons. Arbutus Biopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×10×20×3008784123300016301211000566INNOVACAPORCHPHARMA300194603567185750301096ABUSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Arbutus Biopharma is the large dot.

Arbutus Biopharma competitors and peer comparison

How Arbutus Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arbutus Biopharma against its 20 peers (data as of 18 Nov 2026)
MeasureABUSPeer medianRank in peer set
1-month return-5.1%-10.7%8th highest of 20
6-month return-6.0%-25.9%5th highest of 20
Distance from 52-week high-24.6%-39.9%5th highest of 20
Revenue growth (TTM)+1,142.6%+5.5%highest of 17
Operating margin80.1%4.4%highest of 16
EV / Sales1.6×3.3×3rd cheapest of 17
EV / EBITDA2.0×14.5×cheapest of 6
Net debt / EBITDA-2.3×0.7×least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a

Questions

Which companies are Arbutus Biopharma's closest peers?
The cockpit's peer set: Zhejiang Wecome Pharmaceutical (300878.SZ), Bicara Therapeutics (BCAX), Center Laboratories (4123.TWO), Beijing Beilu Pharmaceutical (300016.SZ), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Olema Pharmaceuticals (OLMA), Hainan Haiyao (000566.SZ), Innova Captab (INNOVACAP.NS).
Is Arbutus Biopharma expensive compared with its peers?
On ev / sales it trades at 1.6× against a peer median of 3.3×, 3rd cheapest of 17 in its peer set.
How has Arbutus Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -6.0% against -25.9% for the median peer; over one year -9.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.